Sun Pharma Q4 Review: Strong Domestic Growth Offset By Weakness In US Generics; Systematix Maintains 'Buy'

Sun Pharma has also guided for an investment of $100 million in new launches. During the year, besides new launches, Sun Pharma will also unveil important clinical data on its new chemical entity pipeline (Vibozilimod, Ilumya in psoriatic arthritis) and the clinical data should be important as it would shape sentiment around medium to long term growth..NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Systematix Report.Sun Pharmaceutical Industries Ltd.’s adjusted earnings stood at Rs 28,891 million which was below our expectations owing to weakness in US generics (as gRevlimid contribution was immaterial) and a higher effective tax rate (19.8% in Q4 FY25 vs 5.1% in Q4 FY24). Going forward tax rate will remain at current levels/inch up higher as Sun Pharma has exhausted tax benefits on losses. For FY26 Sun Pharma is guiding for mid to high single digit revenue growth considering global uncertainties (currency volatility, US regulatory uncertainties) and the company would be in the midst of building multiple new launches on the speciality front (Nidlegy, Leqselvi and cosibelimab). Sun Pharma has also guided for an investment of $100 million in new launches. During the year, besides new launches, Sun Pharma will also unveil important clinical data on its new chemical entity pipeline (Vibozilimod, Ilumya in psoriatic arthritis) and the clinical data should be important as it would shape sentiment around medium to long term growth. We tweak our estimates to account for the updated tax guidance and contribution from new launches on the specialty front. Based on our revised estimates, we maintain Buy on Sun Pharma, retaining our target price of 2,206, based on 35x FY27E EPS..Click on the attachment to read the full report:.Sun Pharma Q4 Review: Brokerages Stay Bullish Despite Soft FY26 Guidance.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Sun Pharma Q4 Review: Strong Domestic Growth Offset By Weakness In US Generics; Systematix Maintains 'Buy'

Systematix tweaks its estimates to account for the updated tax guidance and contribution from new launches on the specialty front.

NDTV Profit

NDTV Profit

Follow Us

DISCOVER US FASTER

DOWNLOAD THE APP